AN2 Historical Income Statement

ANTX Stock

USD 1.37 0.02 1.44%

Historical analysis of AN2 Therapeutics income statement accounts such as Interest Expense of 620.7 K, Selling General Administrative of 7.7 M or Selling And Marketing Expenses of 17.8 M can show how well AN2 Therapeutics performed in making a profits. Evaluating AN2 Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of AN2 Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining AN2 Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether AN2 Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AN2 Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy AN2 Stock please use our How to Invest in AN2 Therapeutics guide.

About AN2 Income Statement Analysis

AN2 Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to AN2 Therapeutics shareholders. The income statement also shows AN2 investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

AN2 Therapeutics Income Statement Chart

At this time, AN2 Therapeutics' Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to rise to about 620.7 K in 2024, whereas Selling General Administrative is likely to drop slightly above 7.7 M in 2024.

Selling General Administrative Selling And Marketing Expenses Other Operating Expenses Research Development

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of AN2 Therapeutics. It is also known as AN2 Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from AN2 Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into AN2 Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AN2 Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy AN2 Stock please use our How to Invest in AN2 Therapeutics guide.At this time, AN2 Therapeutics' Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to rise to about 620.7 K in 2024, whereas Selling General Administrative is likely to drop slightly above 7.7 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Income	69K	1.4M	1.6M	1.6M
Net Interest Income	69K	1.4M	1.6M	1.6M

Interest Income Net Interest Income

AN2 Therapeutics income statement Correlations

	Depreciation And Amortization	Selling General Administrative	Selling And Marketing Expenses	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Net Interest Income	Interest Income	Net Income From Continuing Ops	Gross Profit	Cost Of Revenue
Depreciation And Amortization		0.27	0.04	0.53	-0.51	-0.84	0.57	0.76	0.53	-0.47	0.73	-0.47	-0.47	0.47	0.47	-0.53	0.75	-0.76
Selling General Administrative	0.27		0.75	0.89	-0.91	-0.64	0.87	-0.28	0.89	-0.91	0.7	-0.91	0.48	0.92	0.92	-0.91	0.74	-0.54
Selling And Marketing Expenses	0.04	0.75		0.82	-0.82	-0.2	0.81	-0.23	0.82	-0.86	0.35	-0.86	0.27	0.77	0.77	-0.8	0.6	-0.61
Other Operating Expenses	0.53	0.89	0.82		-1.0	-0.73	1.0	0.03	1.0	-0.99	0.8	-0.99	0.19	0.97	0.97	-1.0	0.86	-0.86
Operating Income	-0.51	-0.91	-0.82	-1.0		0.72	-1.0	-0.01	-1.0	1.0	-0.79	1.0	-0.21	-0.97	-0.97	1.0	-0.87	0.84
Ebit	-0.84	-0.64	-0.2	-0.73	0.72		-0.74	-0.3	-0.73	0.67	-0.94	0.67	-0.02	-0.74	-0.74	0.75	-0.76	0.72
Research Development	0.57	0.87	0.81	1.0	-1.0	-0.74		0.08	1.0	-0.99	0.81	-0.99	0.13	0.96	0.96	-0.99	0.88	-0.88
Ebitda	0.76	-0.28	-0.23	0.03	-0.01	-0.3	0.08		0.03	0.01	0.16	0.02	-0.86	-0.09	-0.09	-0.01	0.42	-0.42
Total Operating Expenses	0.53	0.89	0.82	1.0	-1.0	-0.73	1.0	0.03		-0.99	0.8	-0.99	0.19	0.97	0.97	-1.0	0.86	-0.86
Income Before Tax	-0.47	-0.91	-0.86	-0.99	1.0	0.67	-0.99	0.01	-0.99		-0.75	1.0	-0.22	-0.97	-0.97	0.99	-0.86	0.83
Total Other Income Expense Net	0.73	0.7	0.35	0.8	-0.79	-0.94	0.81	0.16	0.8	-0.75		-0.74	0.03	0.77	0.77	-0.81	0.74	-0.74
Net Income	-0.47	-0.91	-0.86	-0.99	1.0	0.67	-0.99	0.02	-0.99	1.0	-0.74		-0.23	-0.97	-0.97	0.99	-0.85	0.82
Income Tax Expense	-0.47	0.48	0.27	0.19	-0.21	-0.02	0.13	-0.86	0.19	-0.22	0.03	-0.23		0.38	0.38	-0.23	-0.18	0.18
Net Interest Income	0.47	0.92	0.77	0.97	-0.97	-0.74	0.96	-0.09	0.97	-0.97	0.77	-0.97	0.38		1.0	-0.98	0.79	-0.79
Interest Income	0.47	0.92	0.77	0.97	-0.97	-0.74	0.96	-0.09	0.97	-0.97	0.77	-0.97	0.38	1.0		-0.98	0.79	-0.79
Net Income From Continuing Ops	-0.53	-0.91	-0.8	-1.0	1.0	0.75	-0.99	-0.01	-1.0	0.99	-0.81	0.99	-0.23	-0.98	-0.98		-0.87	0.83
Gross Profit	0.75	0.74	0.6	0.86	-0.87	-0.76	0.88	0.42	0.86	-0.86	0.74	-0.85	-0.18	0.79	0.79	-0.87		-0.8
Cost Of Revenue	-0.76	-0.54	-0.61	-0.86	0.84	0.72	-0.88	-0.42	-0.86	0.83	-0.74	0.82	0.18	-0.79	-0.79	0.83	-0.8

Click cells to compare fundamentals

AN2 Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for AN2 Stock Analysis

When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

AN2 Historical Income Statement

About AN2 Income Statement Analysis

AN2 Therapeutics Income Statement Chart

Other Operating Expenses

AN2 Therapeutics income statement Correlations

AN2 Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for AN2 Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Depreciation And Amortization	Interest Expense
Selling General Administrative	Selling And Marketing Expenses
Other Operating Expenses	Operating Income
Ebit	Research Development
Ebitda	Total Operating Expenses
Income Before Tax	Total Other Income Expense Net
Net Income Applicable To Common Shares	Net Income
Income Tax Expense	Net Interest Income
Interest Income	Total Revenue
Net Income From Continuing Ops	Gross Profit
Cost Of Revenue

Research Development	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses
Income Before Tax	+ 1.0	Operating Income
Net Income	+ 1.0	Operating Income
Net Income From Continuing Ops	+ 1.0	Operating Income
Total Operating Expenses	+ 1.0	Research Development

Net Income From Continuing Ops	- 1.0	Total Operating Expenses
Total Operating Expenses	- 1.0	Operating Income
Research Development	- 1.0	Operating Income
Net Income From Continuing Ops	- 1.0	Other Operating Expenses
Operating Income	- 1.0	Other Operating Expenses
Net Income	- 0.99	Total Operating Expenses